The trajectory of Viagra presents a challenging picture for shareholders. While the initial launch generated significant profits, the lapse of its patent opened the door to generic versions, dramatically eroding revenue. This presents a unique risk for pharmaceutical companies depending on comparable blockbuster medications, suggesting that a carel

The history of Viagra, and its creator copyright, presents a challenging case study for investors. Initially a blockbuster drug, producing billions in sales , its patent expiration created a flood of lower-priced alternatives , significantly diminishing its dominance. While some firms may seek to capitalize on similar conditions , the current lands